On January 3, 2020 NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, reported that it will present a company overview at the Biotech Showcase 2020 conference, taking place at the Hilton Union Square in San Francisco, CA (Press release, NeoImmuneTech, JAN 3, 2020, View Source [SID1234552686]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NeoImmuneTech’s Chief Business Officer, Samuel Zhang, Ph.D., MBA, will review NeoImmuneTech’s recent progress and future directions, including an update on the company’s lead drug candidate, Hyleukin-7. NeoImmuneTech is currently conducting several clinical trials of Hyleukin-7 in different types of cancer and multiple pre-IND and non-clinical studies in both solid tumors and hematologic malignancies.
Presentation details:
Date: Tuesday, January 14
Time: 3:00pm PT
Track: Franciscan B (Ballroom Level)
Location: Hilton Hotel, Downtown San Francisco, CA
About Hyleukin-7
Hyleukin-7, the only clinical-stage long-acting human IL-7, is uniquely positioned to address unmet medical needs in immuno-oncology. IL-7 is a fundamental cytokine for T-cell development and for sustaining immune response to chronic antigens (as in cancer). Hyleukin-7’s favorable PK/PD and safety profiles make it an ideal combination partner for immunotherapy standard of care (SOC) such as Checkpoint Inhibitor and CAR-T therapies. Hyleukin-7 is being studied in multiple clinical trials in solid tumors, and is being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.